News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 73–108
- Matches
- 135
- Sources here
- 22
- Companies here
- 9
Search results
Stored financial headlines
Active search
135 matching headlines
Ticker or company: EKTMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Nektar Therapeutics Initiated at Buy by Canaccord Genuity
Canaccord Genuity has initiated coverage on Nektar Therapeutics with a "Buy" rating. This indicates an optimistic outlook from the investment firm regarding the pharmaceutical company's future stock performance. Further details regarding specific price targets or reasons for the rating were not provided in this …
NKTR
main company
Sharemaestro market context
Trend signal active
52 weeks +170.1%
NKTR Up on Start of Phase III Program on Rezpeg for Atopic Dermatitis
Nektar Therapeutics (NKTR) announced the initiation of phase III clinical trials (ZENITH AD-1 and ZENITH AD-2) for its drug candidate, rezpegaldesleukin (rezpeg), to treat moderate-to-severe atopic dermatitis. The company's shares rose following the news, and rezpeg is also being developed for other autoimmune diseases …
NKTR
main company
Sharemaestro market context
Trend signal active
52 weeks +170.1%
Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Nektar Therapeutics (NASDAQ:NKTR) securities. The investigation focuses on whether Nektar and its officers engaged in corporate wrongdoing, particularly for investors who purchased shares before February 26, 2025, and still hold …
NKTR
main company
Sharemaestro market context
Trend signal active
52 weeks +170.1%
Nektar Therapeutics Starts Phase 3 ZENITH AD Program Evaluating Rezpegaldesleukin in Moderate-to-Severe AD
Nektar Therapeutics has launched its Phase 3 ZENITH AD program for rezpegaldesleukin, aimed at treating moderate-to-severe atopic dermatitis in patients aged 12 and older. The program includes three global trials, with ZENITH AD-1 and ZENITH AD-2 focusing on treatment-naive patients, and ZENITH AD-3 on …
NKTR
main company
Sharemaestro market context
Trend signal active
52 weeks +170.1%
Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Nektar Therapeutics (NASDAQ:NKTR) due to suspected corporate wrongdoing. The firm is encouraging shareholders who purchased NKTR securities before February 26, 2025, and still hold them, to join their securities investigation. The firm operates on …
NKTR
main company
Sharemaestro market context
Trend signal active
52 weeks +170.1%
Enterprise value to EBIT forward of Nektar Therapeutics – BMV:NKTR
This article displays financial data for Nektar Therapeutics (BMV:NKTR), specifically its Enterprise Value to EBIT forward. It appears to be a financial snapshot from TradingView, showing the absence of trades and outlining the company's financial overview within the health technology and pharmaceutical sectors. The …
NKTR
main company
Sharemaestro market context
Trend signal active
52 weeks +170.1%
Nektar Therapeutics (NKTR) Stock Looks Above Fair Value Despite Its 7x Run
Nektar Therapeutics (NKTR) has seen a significant 7x return over the last three years but is currently screening as overvalued according to Simply Wall St's analysis. The company's P/S ratio of 41.5x is considerably higher than the industry average and its estimated fair P/S …
NKTR
main company
Sharemaestro market context
Trend signal active
52 weeks +170.1%
Price to sales forward of Nektar Therapeutics – BMV:NKTR
This article provides financial information for Nektar Therapeutics (NKTR) on the Mexican Stock Exchange, focusing on its price-to-sales forward metric. It highlights that the market is closed with no recent trades. The content is primarily a data page from TradingView, offering an overview of …
NKTR
main company
Sharemaestro market context
Trend signal active
52 weeks +170.1%
ETFs Investing in Nektar Therapeutics Stocks
This article provides a comprehensive list of ETFs that hold Nektar Therapeutics (NKTR) stocks, detailing their market value, weight, issuer, management style, focus, expense ratio, AUM, price, and 3-year NAV total return. The ETFs listed predominantly focus on small-cap, extended market, or healthcare sectors, …
NKTR
main company
Sharemaestro market context
Trend signal active
52 weeks +170.1%